Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Omalizumab, a monoclonal antibody against IgE for the treatment of allergic diseases
Autore:
Soler, M;
Indirizzi:
Univ Basel Hosp, Div Pulm, CH-4031 Basel, Switzerland Univ Basel Hosp Basel Switzerland CH-4031 lm, CH-4031 Basel, Switzerland
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 7, volume: 55, anno: 2001,
pagine: 480 - 483
SICI:
1368-5031(200109)55:7<480:OAMAAI>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
FC-EPSILON-RI; ASTHMATIC SUBJECTS; COMPLEX-FORMATION; DOWN-REGULATION; IN-VIVO; RHINITIS; RESPONSES; E25;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Soler, M Univ Basel Hosp, Div Pulm, CH-4031 Basel, Switzerland Univ Basel Hosp Basel Switzerland CH-4031 31 Basel, Switzerland
Citazione:
M. Soler, "Omalizumab, a monoclonal antibody against IgE for the treatment of allergic diseases", INT J CL PR, 55(7), 2001, pp. 480-483

Abstract

Omalizumab, a recombinant, humanised monoclonal antibody against human IgE, will be introduced soon for the treatment of allergic asthma. This antibody binds circulating IgE molecules and inhibits the type I immune response in the lung and other target organs. In the phase II and III studies performed, it demonstrated a significant and important effect in controlling and stabilising asthma by reducing exacerbations and the need for inhaled corticosteroids. The safety and tolerability up to one year of treatment were very good. This new treatment may have a role in patients with difficult-to-control asthma, with recurrent exacerbations, and those with concurrent asthma, nose and eye symptoms.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 23:05:13